<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>Tyra Biosciences</title>
    <link>https://www.biospace.com/employer/3076400/tyra-biosciences</link>
    <description>Tyra Biosciences</description>
    <language>en-US</language>
    <lastBuildDate>Mon, 13 Jan 2020 13:07:01 GMT</lastBuildDate>
    <atom:link href="https://www.biospace.com/employer/3076400/tyra-biosciences.rss" type="application/rss+xml" rel="self" />
    <item>
      <title>Tyra Biosciences Raises $50 Million to Focus on Cancer Drug Resistance</title>
      <link>https://www.biospace.com/tyra-biosci-closes-series-a-financing-worth-50-million</link>
      <dc:creator>Mark Terry</dc:creator>
      <description>Tyra Biosciences, based in Carlsbad, California, closed on a Series A financing worth $50 million.</description>
      <pubDate>Mon, 13 Jan 2020 13:07:01 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosci-closes-series-a-financing-worth-50-million</guid>
    </item>
    <item>
      <title>Working to Tackle Drug Resistance in Oncology Patients, Tyra Aims for $100 Million IPO</title>
      <link>https://www.biospace.com/working-to-tackle-drug-resistance-in-oncology-patients-tyra-aims-for-100-million-ipo</link>
      <dc:creator>Ellen Bombela</dc:creator>
      <description>Tyra Biosciences aspires to raise a $100 million IPO, according to its S-1 form filed with the U.S. Securities and Exchange commission late last week.</description>
      <pubDate>Tue, 24 Aug 2021 14:12:58 GMT</pubDate>
      <guid>https://www.biospace.com/working-to-tackle-drug-resistance-in-oncology-patients-tyra-aims-for-100-million-ipo</guid>
    </item>
    <item>
      <title>Tyra Biosciences Announces Planned Chief Financial Officer Transition</title>
      <link>https://www.biospace.com/tyra-biosciences-announces-planned-chief-financial-officer-transition</link>
      <description>Tyra Biosciences, Inc. announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.</description>
      <pubDate>Wed, 02 Nov 2022 19:06:26 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-announces-planned-chief-financial-officer-transition</guid>
    </item>
    <item>
      <title>Tyra Biosciences Reports Third Quarter 2022 Financial Results and Highlights</title>
      <link>https://www.biospace.com/tyra-biosciences-reports-third-quarter-2022-financial-results-and-highlights</link>
      <description>Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter ended September 30, 2022 and highlighted recent corporate progress.</description>
      <pubDate>Thu, 03 Nov 2022 19:06:36 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-reports-third-quarter-2022-financial-results-and-highlights</guid>
    </item>
    <item>
      <title>Tyra Biosciences to Present at Upcoming Investor Conferences</title>
      <link>https://www.biospace.com/tyra-biosciences-to-present-at-upcoming-investor-conferences</link>
      <description>Tyra Biosciences, Inc. today announced that the Company will be presenting and hosting one-on-one meetings at the following conferences in November.</description>
      <pubDate>Thu, 10 Nov 2022 21:26:03 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-to-present-at-upcoming-investor-conferences</guid>
    </item>
    <item>
      <title>Tyra Biosciences Initiates SURF301 Phase 1/2 Clinical Study and Doses First Patient with TYRA-300</title>
      <link>https://www.biospace.com/tyra-biosciences-initiates-surf301-phase-1-2-clinical-study-and-doses-first-patient-with-tyra-300</link>
      <description>Tyra Biosciences, Inc. today announced the initiation of its SURF301 Phase 1/2 clinical study, with first patient dosed with TYRA-300.</description>
      <pubDate>Tue, 29 Nov 2022 12:06:17 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-initiates-surf301-phase-1-2-clinical-study-and-doses-first-patient-with-tyra-300</guid>
    </item>
    <item>
      <title>Tyra Biosciences to Present at Upcoming March 2023 Investor Conferences</title>
      <link>https://www.biospace.com/tyra-biosciences-to-present-at-upcoming-march-2023-investor-conferences</link>
      <description>Tyra Biosciences, Inc. announced that management will present at the following investor conferences.</description>
      <pubDate>Wed, 22 Feb 2023 21:06:12 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-to-present-at-upcoming-march-2023-investor-conferences</guid>
    </item>
    <item>
      <title>Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia</title>
      <link>https://www.biospace.com/tyra-biosciences-expands-development-of-tyra-300-an-oral-fgfr3-selective-agent-into-achondroplasia</link>
      <description>Tyra Biosciences, Inc. today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Imagine Institute in Paris, France.</description>
      <pubDate>Wed, 01 Mar 2023 12:06:33 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-expands-development-of-tyra-300-an-oral-fgfr3-selective-agent-into-achondroplasia</guid>
    </item>
    <item>
      <title>Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights</title>
      <link>https://www.biospace.com/tyra-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlights</link>
      <description>Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter and year ended December 31, 2022, and highlighted recent corporate progress.</description>
      <pubDate>Wed, 22 Mar 2023 19:06:13 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-reports-fourth-quarter-and-full-year-2022-financial-results-and-highlights</guid>
    </item>
    <item>
      <title>Tyra Biosciences to Participate in Upcoming Investor Conferences - March 29, 2023</title>
      <link>https://www.biospace.com/tyra-biosciences-to-participate-in-upcoming-investor-conferences-march-29-2023</link>
      <description>Tyra Biosciences, Inc. announced that management will present and participate in the following investor conferences.</description>
      <pubDate>Wed, 29 Mar 2023 20:06:17 GMT</pubDate>
      <guid>https://www.biospace.com/tyra-biosciences-to-participate-in-upcoming-investor-conferences-march-29-2023</guid>
    </item>
  </channel>
</rss>
